Tetra Collaboration Aims to Bring Investigational Cannibinoid Therapy to Canadian Fibromyalgia Patients

Tetra Collaboration Aims to Bring Investigational Cannibinoid Therapy to Canadian Fibromyalgia Patients
Tetra Bio-Pharma has announced an agreement with Storz & Bickel to use a specialty medical device known as the Mighty Medic in the development of its investigational PPP001 therapy for pain relief in patients with fibromyalgia and other chronic pain conditions. Mighty Medic is a Health Canada-approved portable herbal vaporizer for the use of cannabis. PPP001 — a cannabinoid-based product — is currently being tested in a Phase 3 clinical trial (NCT03339622) for pain relief in late-stage cancer patients. Tetra aims for it to be the first smokeable cannabinoid product available by prescription in Canada to treat advanced cancer pain. This new collaboration will allow the company to expand the market potential for PPP001 to patients with other chronic pain conditions, such as fibromyalgia. Fibromyalgia patients experience significant pain that can be deep, sharp, dull, throbbing, or aching. The pain can occur in multiple regions throughout the body including muscles, tendons, and ligaments. “Fibromyalgia is difficult to treat and there is no one 'magic bullet.' As practitioners we have the daunting task of moving our patients from unrelenting neuropathic pain to improved function and a better quality of life,” Gordon D. Ko, MD, PhD, medical director of fibromyalgia clinics at The Canadian Centre for Integrative Medicine and Sunnybrook Health Sciences Centre, said in a press release. Current treatments for pain relief in fibromyalgia patients increasingly include the use of opioids — which can lead to significant negative long-term effects. Some of the most common prescription medications include Lyrica (pregabalin), Cymbalta (duloxetine), Xyrem (sodium oxybate), and Vimpat (lacosamide). A potentially safer strategy for pain relief may be th
Subscribe or to access all post and page content.